28.3 C
New York
Monday, July 21, 2025
Home Tags NYSE

Tag: NYSE

Maxar Technologies – Stock took a beating despite of positive news,...

0
Shares of Maxar Technologies (NYSE: MAXR) rose by almost 28% on May 23, before plunging 10%, summing up what turned out to be a rollercoaster...

Fair Prospects ahead for Sirona Biochem with Grant of Key Patent...

0
Sirona Biochem (OTCPK: SRBCF), a biopharmaceutical company focused on discovering novel cosmetic and pharmaceutical compounds, announced the grant of a patent for TFC-1067, its...

Gene Therapy offers Cure for Bubble Boy Syndrome

0
Severe combined immunodeficiency (SCID) or “Bubble Boy Syndrome” is a rare genetic disorder caused by gene mutations that inhibit the functioning of immune cells....

ReWalk Raises $5M for its ReStore Exosuit for Stroke Victims

0
Standing Tall ReWalk Robotics (NASDAQ: RWLK) recently received an approval for its ReStore exoskeleton system, indicated for rehabilitation of stroke victims, from the FDA. The company...

The Emerging Paradigm in HIV Therapeutics Offers Hope for a Cure

0
Human Immunodeficiency Virus (HIV) compromises the body’s immunity by attacking CD4 cells (a type of T cell), exposing it to a host of infections...

Obalon Granted First US Patent for its Proprietary Intragastric Balloon System.

0
Obalon Therapeutics (NASDAQ: OBLN), the manufacturer of the first and only FDA-approved swallowable, gas-filled intragastric balloon system to combat obesity, has announced the grant...

Research in Biologics and Small Molecules aim to unravels the genetics...

0
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes the body’s immune system to attack healthy tissue causing inflammation, photosensitivity, oral ulcers, pleuritis,...

Can Cara Therapeutics buck the trend?

0
Cara Therapeutics (NASDAQ: CARA) recently posted its first quarter, 2019 results. The company reported a net loss of $22.0 million, or $0.56 per basic...

G1 Therapeutics stock soars on news of NDA for Triaciclib

0
G1 Therapeutics (NASDAQ: GTHX) shares soared by almost 25% on the basis of news that it had a productive phase 2 meeting with the...

Curaleaf Holding: Forging the largest acquisition in U.S cannabis landscape

0
The shares of Curaleaf (OTCQX: CURLF) surged by almost 15% since the news of its acquisition of Cura Partners, the owner of Select brand, in...